Highlights

  • Epiminder (ASX:EPI) is developing and commercialising the Minder implantable continuous EEG monitoring system for people with drug-resistant epilepsy.
  • The US DETECT study reached 50 patient enrolments in July 2026, ahead of the company’s previously stated milestone.
  • Minder has FDA authorisation, while US Medicare reimbursement provides an important foundation for the commercial pathway.
  • DETECT enrolment, next-generation product development and clinician adoption will be central to the next stage.

Epiminder (ASX:EPI) is developing a differentiated medical-device platform aimed at improving how epilepsy is monitored over extended periods. Its Minder System is a minimally invasive implantable continuous electroencephalography monitoring technology designed to record brain activity while patients continue with everyday life.

Rather than relying only on short monitoring periods in hospitals, Minder is designed to provide clinicians with longitudinal EEG information over months or potentially years. That proposition gives Epiminder exposure to a significant clinical challenge in epilepsy management, particularly for patients whose seizure activity can be difficult to capture and quantify accurately.

An advancing commercial profile

Epiminder (ASX:EPI) has progressed materially beyond the early development stage described in the original article.

The Minder System received US FDA De Novo authorisation in April 2025, creating a new device classification and allowing the system to be marketed in the United States for patients with drug-resistant epilepsy. The device also received Breakthrough Device designation from the FDA.

Commercialisation efforts accelerated during 2026. The first US patient was implanted with Minder in January at the University of Pennsylvania as part of the DETECT clinical study, representing an important transition from regulatory authorisation towards broader clinical deployment.

The Investment case is therefore increasingly centred on whether clinical adoption and reimbursement progress can translate the technology into a scalable commercial platform.

Why DETECT matters

The DETECT study is one of the most important components of Epiminder’s commercialisation strategy.

DETECT is a prospective, randomised and controlled US clinical study evaluating whether continuous EEG monitoring with Minder can improve clinical decision-making for patients with drug-resistant epilepsy following an inconclusive conventional EEG assessment.

In July 2026, Epiminder (ASX:EPI) announced that DETECT had enrolled its 50th patient, reaching the milestone ahead of its previously indicated mid-Q3 CY2026 target.

At that stage, 20 leading US clinical sites were actively enrolling patients, including institutions associated with Mayo Clinic, Harvard, Stanford, Yale, Duke and the University of Pennsylvania. The company maintained its target of reaching 210 patients by the end of the first half of calendar 2027.

Continued enrolment is important because DETECT is intended to build evidence around clinical Utility while supporting the broader reimbursement and commercial proposition for Minder.

The technology and evidence base

Minder’s key distinction is its ability to collect EEG information continuously over extended periods while patients remain outside a controlled hospital environment.

Traditional EEG testing captures only a limited window of brain activity. That can create challenges when seizure events are infrequent, unreported or difficult to distinguish accurately from other symptoms.

Epiminder’s technology seeks to address that limitation by generating substantially longer-term physiological data.

The company’s clinical evidence includes the UMPIRE study, which demonstrated the ability of its bilateral sub-scalp system to capture durable EEG signals over extended periods. The study reported clinically relevant findings in 88% of patients and produced signals comparable with conventional scalp EEG monitoring.

For a medical-device company, such evidence is important because commercial adoption ultimately depends on more than regulatory approval. Neurologists, hospitals and payers need confidence that the technology can improve clinical decision-making and patient management.

Reimbursement strengthens the pathway

Reimbursement is another significant part of Epiminder’s US strategy.

During FY2026, the company received a final Medicare ruling setting reimbursement for implantation of the Minder device at approximately US$27,700 for 2026, an increase from the preliminary reimbursement level.

Management indicated that this supports the US$25,000 average selling price assumption used in its commercial planning.

For medical-device businesses, reimbursement can be as important as regulatory approval. A product may have compelling clinical characteristics, but meaningful adoption can remain difficult if hospitals and clinicians lack a workable reimbursement pathway.

Epiminder therefore enters its next stage with both FDA authorisation and a defined reimbursement framework supporting the US commercial proposition.

Funding and next-generation development

Epiminder (ASX:EPI) also strengthened its Capital position through the A$125 million raising completed when it listed on the ASX in December 2025.

At its interim FY2026 update, the company reported A$89.5 million in cash at 31 December 2025 and said it had sufficient resources to fund the DETECT programme and development of its next-generation Minder system well into 2028.

That next-generation programme, known as G1, is another important element of the longer-term strategy. Engineering completion has been targeted for the end of FY2027, with hardware development and biocompatibility testing forming part of the programme.

The funding position therefore gives Epiminder a degree of flexibility to advance both clinical evidence generation and product development without depending solely on near-term commercial revenue.

What to watch next

The most important indicators are now clinical and commercial.

Continued DETECT enrolment towards the 210-patient target will be a key measure of execution. The breadth of participating US medical centres and the pace of patient recruitment will also provide insight into clinician engagement.

Investors will also be watching the progression of the G1 Minder platform, further reimbursement developments and evidence that FDA authorisation is translating into increasing clinical use.

Ultimately, commercial adoption will depend on neurologists and epilepsy centres seeing enough clinical value in continuous monitoring to integrate Minder into patient-management pathways.

Key risks

The risks remain meaningful despite the regulatory and clinical progress.

Epiminder (ASX:EPI) is still building its commercial model, and widespread adoption of an implantable medical device can take time. Clinicians must become familiar with the technology, hospitals need appropriate workflows, and payers must continue to support reimbursement.

The DETECT programme also carries execution risk. Recruitment can take longer than expected, while study outcomes may not demonstrate the level of clinical or economic benefit anticipated.

Competition is another consideration. Large medical-device and diagnostic companies possess substantial distribution networks, clinical relationships and financial resources.

Product development risk remains as well, particularly as Epiminder advances its next-generation platform. Regulatory requirements, Manufacturing scale-up and technical performance could all influence development timelines and costs.

On balance, Epiminder (ASX:EPI) has moved beyond being simply an early-stage implantable neurotechnology story. Minder has FDA authorisation, US reimbursement infrastructure is developing, and DETECT is progressing through a growing network of leading clinical centres. The next phase will depend on whether those foundations can translate into convincing clinical utility, broader adoption and an increasingly scalable commercial model.